Deep vein thrombosis (DVT) is a blood clot that forms in a deep vein, usually in the leg, causing pain, swelling, and redness. The most serious complication is pulmonary embolism if the clot breaks off and travels to the lungs, and a significant proportion of patients develop post-thrombotic syndrome with chronic leg pain and swelling months to years after the acute event.
What's actually going on in research
Direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban, and dabigatran have replaced warfarin as standard therapy for most DVT patients due to convenience and comparable or better safety. Trials are studying catheter-directed thrombolysis to reduce post-thrombotic syndrome, optimal anticoagulation duration in different risk groups, and drugs that block clotting without increasing bleeding risk by targeting factor XI rather than factor Xa or thrombin.
Factor XI inhibitors
Drugs blocking factor XI — a coagulation factor that contributes to pathological clotting but less to normal hemostasis — are in late-stage trials, potentially offering anticoagulation with substantially lower bleeding risk than current drugs.
Catheter-directed thrombolysis
Trials are evaluating whether delivering clot-dissolving drugs directly into the deep venous clot via catheter reduces the risk of post-thrombotic syndrome compared to anticoagulation alone, despite earlier neutral results.
Anticoagulation duration
The optimal duration of anticoagulation after a first DVT — particularly in patients with unprovoked clots or those at moderate recurrence risk — is being refined in trials using recurrence biomarkers to guide treatment length.
What to know before you search
Eligibility depends on clot location and extent, prior venous thromboembolism, provoking factors such as surgery or cancer, and bleeding risk.
What types of trials are currently open
- Factor XI inhibitor trials — Testing novel anticoagulants targeting factor XI to prevent clots with potentially less bleeding.
- Catheter-directed therapy trials — Evaluating lytic drugs delivered directly to clots to reduce post-thrombotic syndrome.
- Anticoagulation duration trials — Determining optimal treatment length for different DVT types and patient risk profiles.
- Post-thrombotic syndrome trials — Testing compression, exercise, and drug interventions to reduce chronic leg complications after DVT.
- Prevention trials — Studying anticoagulant strategies to prevent DVT in high-risk surgical, medical, and ambulatory patients.
Recently added Deep Vein Thrombosis trials
Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery
The goal of this observational study is to learn about the risk factors and prediction of postoperative venous thromboembolism (VTE) in patients undergoing lung cancer surgery. The main question it aims to answer is: Which clinical, surgical, and laboratory factors are associated with the development of postoperative deep vein thrombosis (DVT) in lung cancer surgery patients, and can machine learning models accurately predict individual risk? Participants undergoing lung cancer surgery will be prospectively followed for 30 days after surgery. Perioperative clinical data, laboratory results, and imaging findings will be collected to identify VTE risk factors and to develop a predictive model.
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Find Deep Vein Thrombosis trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.